Late growth of infantile hemangiomas in children >3 years of age: A retrospective study - 14/01/19
Abstract |
Background |
The proliferative phase of infantile hemangiomas (IHs) is usually complete by 9 months of life. Late growth beyond age 3 years is rarely reported.
Objective |
To describe the demographic and clinic characteristics of a cohort of patients with late growth of IH, defined as growth in a patient >3 years of age.
Methods |
A multicenter, retrospective cohort study.
Results |
In total, 59 patients, 85% of which were female, met the inclusion criteria. The mean first episode of late growth was 4.3 (range 3-8.5) years. Head and neck location (55/59; 93%) and presence of deep hemangioma (52/59; 88%) were common characteristics. Posterior fossa malformations, hemangiomas, arterial anomalies, cardiac defects, eye abnormalities (PHACE) syndrome was noted in 20 of 38 (53%) children with segmental facial IH. Systemic therapy (corticosteroid or β-blocker) was given during infancy in 58 of 59 (98%) and 24 of 59 (41%) received systemic therapy (β-blockers) for late IH growth.
Limitations |
The retrospective nature and ascertainment by investigator recall are limitations of the study.
Conclusion |
Late IH growth can occur in children after 3 years of age. Risk factors include head and neck location, segmental morphology, and involvement of deep dermal/subcutaneous tissues.
Le texte complet de cet article est disponible en PDF.Key words : β-blocker, corticosteroid, growth hormone, infantile hemangioma, late growth, segmental morphology
Abbreviations used : GH, GHR, HemSCs, IH, PHACE
Plan
Funding sources: None. |
|
Conflicts of interest: Dr Pope is an advisory board member and investigator grant recipient for Pierre Fabre. Dr Blei is a consultant, advisory board member, grant recipient, and speaker for Pierre Fabre. Dr McCuaig is an advisory board member and speaker for Pierre Fabre. Dr Poole is a speaker for Pierre Fabre. Dr Frieden has previously been a consultant for Pierre Fabre. All other authors have no conflicts of interest to disclose. |
|
Previously presented: This work was part of a poster presentation at the 13th World Congress of Pediatric Dermatology in Chicago, Illinois, July 6-9, 2017, and the 22nd International Workshop of the International Society for the Study of Vascular Anomalies in Amsterdam, the Netherlands, May 30-June 1, 2018. |
Vol 80 - N° 2
P. 493-499 - février 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?